Life Science Big News Roundup: BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate; Kalytera Announces Additional Share Issuance for Services under Payments Agreement with Salzman Group

In case you missed it, here is this week’s life science big news roundup: Biotech: BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference Kalytera Announces Additional Share Issuance for Services under Payments Agreement with Salzman […]

BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study

BriaCell has achieved positive proof of concept in the Phase IIa study of Bria-IMT in advanced breast cancer patients Data shows promising anti-tumor activity of Bria-IMT in heavily pre-treated advanced breast cancer patients Impressive Phase IIa efficacy data is similar or superior to those of other approved breast cancer drugs of similar clinical-stage of development […]

BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences

BriaCell Therapeutics Corp. (TSXV:BCT) (OTCQB: BCTXF) (“BriaCell”), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today it will present the data from biomarker analyses of its clinical trials for advanced breast cancer at the Fourth International Cancer Immunotherapy Conference as well as at The MicroCap Conference, both of which will take […]